Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2007-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00432-006-0151-3PMID 17024493PMCID PMC12160859
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [meso-1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]-dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer

  2005cited by this paper
• Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation

  2005cited by this paper
• Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity

  2005cited by this paper
• Effect of zindoxifene on experimental prostatic tumours of the rat

  2005cited by this paper
• The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat

  2005cited by this paper
• [1, 2‐Bis(2, 6‐difluoro‐3‐hydroxyphenyl)ethylene‐diamine]platinum(II) Complexes, Compounds for the Endocrine Therapy of Breast Cancer ‐ Mode of Action II: Contribution of Drug Inactivation, Cellular Drug Uptake and Sterical Factors in the Drug‐Target Interaction to the Antitumor Activity

  2004cited by this paper
• Enantiomerically Pure [1, 2‐Diamino‐1‐(4‐fluorophenyl)butane]platinum(II) Complexes: Synthesis and Antitumor Activity against MCF‐7 and MDA‐MB 231 Breast Cancer and LnCaP/FGC Prostate Cancer Cell Lines

  2004cited by this paper
• Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity

  2004cited by this paper
• Estrogens and anti‐estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates

  2004cited by this paper
• Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta.

  2004cited by this paper
• [1, 2‐Bis(2, 6‐difluoro‐3‐hydroxyphenyl)ethylene‐diamine]platinum(II) Complexes, Compounds for the Endocrine Therapy of Breast Cancer ‐ Mode of Action I: Antitumor Activity Due to the Reduction of the Endogenous Estrogen Level

  2004cited by this paper
• Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk

  2003cited by this paper
• Role of secondary hormonal therapy in the management of recurrent prostate cancer.

  2003influential reference
• Reprints and Subscriptions Permissions

  2003cited by this paper
• Chemotherapy for prostate cancer.

  2002cited by this paper
• Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.

  2002cited by this paper
• Gene expression profiles of genistein-treated PC3 prostate cancer cells.

  2002cited by this paper
• Genitourinary malignancies.

  2001cited by this paper
• Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.

  2000cited by this paper
• The Dunning model

  2000cited by this paper
• Estrogens and prostatic disease

  2000cited by this paper
• Estrogens and prostatic disease. International Prostate Health Council Study Group.

  2000cited by this paper
• Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.

  1999cited by this paper
• Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen

  1999cited by this paper
• Review of phase II hormone refractory prostate cancer trials.

  1999cited by this paper
• [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].

  1998cited by this paper
• Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.

  1998cited by this paper
• A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

  1998cited by this paper
• Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer.

  1997cited by this paper
• Effect of a diphenylethylenediamine platinum complex on steroidogenesis in rats.

  1996cited by this paper
• Mammary Tumor Inhibiting [1,2‐Bis(2,6‐dihalo‐3‐hydroxyphenyl)ethylenediamine]platinum(II) Complexes, III: Relationship between Structure and Estrogenic Activity of the Diamine Ligands, their Sulfatoplatinum (II) and Diiodoplatinum(II) Complexes

  1993cited by this paper
• Breast cancer-inhibiting properties of leaving group derivatives of [1,2-bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine]platinum(II)

  1993cited by this paper
• Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes

  1993cited by this paper
• Breast Cancer Inhibiting Properties of Leaving Group Derivatives of (1, 2-Bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine)platinum(II).

  1993cited by this paper
• Prognostic significance of changes in prostate‐specific markers after endocrine treatment of stage D2 prostatic cancer

  1992cited by this paper
• The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.

  1991cited by this paper
• Computerized determination of growth kinetic curves and doubling times from cells in microculture.

  1990cited by this paper
• Zoladex and Flutamide Versus Bilateral Orchiectomy

  1990cited by this paper
• [1, 2‐bis (2, 6‐dichloro‐4‐hydroxyphenyl) ethylenediamine]dichloro‐platinum(II): An endocrine‐active platinum complex with a specific prostatic tumor‐inhibiting activity

  1989cited by this paper
• Adenocarcinoma of the Prostate

  1988cited by this paper
• The seed stock concept and quality control for cell lines.

  1988cited by this paper
• Konservative Therapie des Prostatakarzinoms

  1987cited by this paper
• Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors.

  1987cited by this paper
• Chemotherapy of Prostatic Cancer

  1987cited by this paper
• Sinn und Unsinn von Therapiekombinationen beim fortgeschrittenen Prostatakarzinom

  1987cited by this paper
• Überblick über die therapeutischen Möglichkeiten des fortgeschrittenen Prostatakarzinoms

  1987cited by this paper
• New principles in the management of metastatic prostatic cancer.

  1985cited by this paper
• The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

  1984cited by this paper
• LNCaP model of human prostatic carcinoma.

  1983cited by this paper
• Hormonal Therapy of Prostatic Cancer

  1980cited by this paper
• [Development of new antiestrogens of the 3,3'-dihydroxy-alpha, beta-diethylstilbene-type and their evaluation on the DMBA-induced hormone dependent mammary carcinoma of the SD-rat (author's transl)].

  1980cited by this paper
• Entwicklung neuer Antiöstrogene vom Typ des 3,3′-Dihydroxy-α,β-diäthylstilbens und ihre Prüfung am DMBA-induzierten, hormonabhängigen Mammacarcinom der SD-Ratte

  1980cited by this paper
• Androgen, estrogen and progesterone receptors of the R3327H Copenhagen rat prostatic tumor.

  1979influential reference
• Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.

  1978cited by this paper
• Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.

  1977cited by this paper
• Experimental models for the study of prostatic adenocarcinoma.

  1977cited by this paper
• Inhibition of hypothalamic obesity in the mouse with diethylstilbestrol.

  1971cited by this paper
• Human prostatic carcinoma: an electron microscope study.

  1966cited by this paper

• Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer

  2025cites this paper
• Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

  2010cites this paper
• Metallodrug Conjugates with Steroids and Selective Estrogen Receptor Modulators (SERM).

  2009cites this paper
• Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases: Part 2: Use of non-steroidal ligands

  2009cites this paper